Notification of the AI ECG algorithm and the A3E scores for Cardiac Amyloidosis
Study Summary
This trial assesses whether a new AI-based tool can improve the diagnosis of cardiac amyloidosis, a heart condition.
- Cardiac Amyloidosis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 1 year
Trial Safety
Trial Design
2 Treatment Groups
Usual Care
1 of 2
Notification of the AI ECG algorithm and the A3E scores
1 of 2
Active Control
Experimental Treatment
200 Total Participants · 2 Treatment Groups
Primary Treatment: Notification of the AI ECG algorithm and the A3E scores · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 19th, 2021
Last Reviewed: November 19th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.